Literature DB >> 25394900

MicroRNA-224 and its target CAMKK2 synergistically influence tumor progression and patient prognosis in prostate cancer.

Hao Fu1, Hui-chan He, Zhao-dong Han, Yue-ping Wan, Hong-wei Luo, Ya-qiang Huang, Chao Cai, Yu-xiang Liang, Qi-shan Dai, Fu-neng Jiang, Wei-de Zhong.   

Abstract

We previously demonstrated that microRNA (miR)-224 expression was significantly reduced in human prostate cancer (PCa) tissues and predicted unfavorable prognosis in patients. However, the underlying mechanisms of miR-224 have not been fully elucidated. In this study, calcium/calmodulin-dependent protein kinase kinase 2 (CAMKK2) was identified as a target gene of miR-224. Then, we found that enforced expression of miR-224 could suppress PCa cell proliferation and cell cycle by regulating the expression of CAMKK2 in vitro. In addition, the expression levels of miR-224 in PCa tissues were negatively correlated with those of CAMKK2 mRNA significantly (Spearman's correlation: r = -0.66, P = 0.004). Moreover, combined low miR-224 expression and high CAMKK2 expression (miR-224-low/CAMKK2-high) was closely correlated with advanced clinical stage (P = 0.028). Furthermore, PCa patients with miR-224-low/CAMKK2-high expression more frequently had shorter overall survival than those in groups with other expression patterns of two molecules. In conclusion, our data offer the convincing evidence that miR-224 and its target gene CAMKK2 may synergistically contribute to the malignant progression of PCa. Combined detection of miR-224 and CAMKK2 expressions represents an efficient predictor of patient prognosis and may be a novel marker which can provide additional prognostic information in PCa.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25394900     DOI: 10.1007/s13277-014-2805-0

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  26 in total

1.  MicroRNA-224 inhibits progression of human prostate cancer by downregulating TRIB1.

Authors:  Zhuo-Yuan Lin; Ya-Qiang Huang; Yan-Qiong Zhang; Zhao-Dong Han; Hui-Chan He; Xiao-Hui Ling; Xin Fu; Qi-Shan Dai; Chao Cai; Jia-Hong Chen; Yu-Xiang Liang; Fu-Neng Jiang; Wei-De Zhong; Fen Wang; Chin-Lee Wu
Journal:  Int J Cancer       Date:  2014-01-10       Impact factor: 7.396

2.  Estimates of cancer incidence and mortality in Europe in 2008.

Authors:  J Ferlay; D M Parkin; E Steliarova-Foucher
Journal:  Eur J Cancer       Date:  2010-01-29       Impact factor: 9.162

3.  The CAMKK2-AMPK kinase pathway mediates the synaptotoxic effects of Aβ oligomers through Tau phosphorylation.

Authors:  Georges Mairet-Coello; Julien Courchet; Simon Pieraut; Virginie Courchet; Anton Maximov; Franck Polleux
Journal:  Neuron       Date:  2013-04-10       Impact factor: 17.173

Review 4.  MicroRNAs in cancer: small molecules with a huge impact.

Authors:  Marilena V Iorio; Carlo M Croce
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

Review 5.  CaMKK2: a novel target for shaping the androgen-regulated tumor ecosystem.

Authors:  Luigi Racioppi
Journal:  Trends Mol Med       Date:  2013-01-14       Impact factor: 11.951

6.  Inhibition of Ca²⁺/calmodulin-dependent protein kinase kinase 2 stimulates osteoblast formation and inhibits osteoclast differentiation.

Authors:  Rachel L Cary; Seid Waddell; Luigi Racioppi; Fanxin Long; Deborah V Novack; Michael J Voor; Uma Sankar
Journal:  J Bone Miner Res       Date:  2013-07       Impact factor: 6.741

7.  Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.

Authors:  M A Eisenberger; B A Blumenstein; E D Crawford; G Miller; D G McLeod; P J Loehrer; G Wilding; K Sears; D J Culkin; I M Thompson; A J Bueschen; B A Lowe
Journal:  N Engl J Med       Date:  1998-10-08       Impact factor: 91.245

8.  The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis.

Authors:  Charles E Massie; Andy Lynch; Antonio Ramos-Montoya; Joan Boren; Rory Stark; Ladan Fazli; Anne Warren; Helen Scott; Basetti Madhu; Naomi Sharma; Helene Bon; Vinny Zecchini; Donna-Michelle Smith; Gina M Denicola; Nik Mathews; Michelle Osborne; James Hadfield; Stewart Macarthur; Boris Adryan; Scott K Lyons; Kevin M Brindle; John Griffiths; Martin E Gleave; Paul S Rennie; David E Neal; Ian G Mills
Journal:  EMBO J       Date:  2011-05-20       Impact factor: 11.598

9.  Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites.

Authors:  Doron Betel; Anjali Koppal; Phaedra Agius; Chris Sander; Christina Leslie
Journal:  Genome Biol       Date:  2010-08-27       Impact factor: 13.583

10.  Global analysis of the differentially expressed miRNAs of prostate cancer in Chinese patients.

Authors:  Hui-chan He; Zhao-dong Han; Qi-shan Dai; Xiao-hui Ling; Xin Fu; Zhuo-yuan Lin; Ye-han Deng; Guo-qiang Qin; Chao Cai; Jia-hong Chen; Fu-neng Jiang; Xingyin Liu; Wei-de Zhong
Journal:  BMC Genomics       Date:  2013-11-05       Impact factor: 3.969

View more
  17 in total

1.  GLUT12 promotes prostate cancer cell growth and is regulated by androgens and CaMKK2 signaling.

Authors:  Mark A White; Efrosini Tsouko; Chenchu Lin; Kimal Rajapakshe; Jeffrey M Spencer; Sandi R Wilkenfeld; Sheiva S Vakili; Thomas L Pulliam; Dominik Awad; Fotis Nikolos; Rajasekhara Reddy Katreddy; Benny Abraham Kaipparettu; Arun Sreekumar; Xiaoliu Zhang; Edwin Cheung; Cristian Coarfa; Daniel E Frigo
Journal:  Endocr Relat Cancer       Date:  2018-02-05       Impact factor: 5.678

2.  A complete map of the Calcium/calmodulin-dependent protein kinase kinase 2 (CAMKK2) signaling pathway.

Authors:  Mohd Altaf Najar; D A B Rex; Prashant Kumar Modi; Nupur Agarwal; Shobha Dagamajalu; Gayathree Karthikkeyan; Manavalan Vijayakumar; Aditi Chatterjee; Uma Sankar; T S Keshava Prasad
Journal:  J Cell Commun Signal       Date:  2020-11-02       Impact factor: 5.782

Review 3.  A spatiotemporal hypothesis for the regulation, role, and targeting of AMPK in prostate cancer.

Authors:  Ayesha S Khan; Daniel E Frigo
Journal:  Nat Rev Urol       Date:  2017-02-01       Impact factor: 14.432

Review 4.  Regulation and role of CAMKK2 in prostate cancer.

Authors:  Thomas L Pulliam; Pavithr Goli; Dominik Awad; Chenchu Lin; Sandi R Wilkenfeld; Daniel E Frigo
Journal:  Nat Rev Urol       Date:  2022-04-26       Impact factor: 14.432

5.  Tyrosine Phosphorylation Profiling Revealed the Signaling Network Characteristics of CAMKK2 in Gastric Adenocarcinoma.

Authors:  Mohd Altaf Najar; Mohammad Arefian; David Sidransky; Harsha Gowda; T S Keshava Prasad; Prashant Kumar Modi; Aditi Chatterjee
Journal:  Front Genet       Date:  2022-05-13       Impact factor: 4.772

6.  Systemic Ablation of Camkk2 Impairs Metastatic Colonization and Improves Insulin Sensitivity in TRAMP Mice: Evidence for Cancer Cell-Extrinsic CAMKK2 Functions in Prostate Cancer.

Authors:  Thomas L Pulliam; Dominik Awad; Jenny J Han; Mollianne M Murray; Jeffrey J Ackroyd; Pavithr Goli; Jonathan S Oakhill; John W Scott; Michael M Ittmann; Daniel E Frigo
Journal:  Cells       Date:  2022-06-10       Impact factor: 7.666

Review 7.  MicroRNA-224: as a potential target for miR-based therapy of cancer.

Authors:  Wei Chen; Xue-Mei Fan; Ling Mao; Jun-Ying Zhang; Jian Li; Jian-Zhong Wu; Jin-Hai Tang
Journal:  Tumour Biol       Date:  2015-08-08

8.  CaMKK2 Suppresses Muscle Regeneration through the Inhibition of Myoblast Proliferation and Differentiation.

Authors:  Cheng Ye; Duo Zhang; Lei Zhao; Yan Li; Xiaohan Yao; Hui Wang; Shengjie Zhang; Wei Liu; Hongchao Cao; Shuxian Yu; Yucheng Wang; Jingjing Jiang; Hui Wang; Xihua Li; Hao Ying
Journal:  Int J Mol Sci       Date:  2016-10-24       Impact factor: 5.923

Review 9.  The potential of microRNAs as human prostate cancer biomarkers: A meta-analysis of related studies.

Authors:  Chun-Jiao Song; Huan Chen; Li-Zhong Chen; Guo-Mei Ru; Jian-Jun Guo; Qian-Nan Ding
Journal:  J Cell Biochem       Date:  2017-12-04       Impact factor: 4.429

10.  Circulating microRNA profiles in plasma: identification of miR-224 as a novel diagnostic biomarker in hepatocellular carcinoma independent of hepatic function.

Authors:  Wataru Okajima; Shuhei Komatsu; Daisuke Ichikawa; Mahito Miyamae; Tsutomu Kawaguchi; Shoji Hirajima; Takuma Ohashi; Taisuke Imamura; Jun Kiuchi; Tomohiro Arita; Hirotaka Konishi; Atsushi Shiozaki; Ryo Moriumura; Hisashi Ikoma; Kazuma Okamoto; Hiroki Taniguchi; Yoshito Itoh; Eigo Otsuji
Journal:  Oncotarget       Date:  2016-08-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.